This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

What’s new

AMPLIFY-EXT Clinical Trial

In AMPLIFY-EXT, in patients receiving extended treatment for prevention of recurrent DVT and PE, ELIQUIS® 2.5 mg BD demonstrated superior efficacy, with no statistically significant increase in the rates of both major and major / CRNM bleeding vs. placebo1,2*

Discover the data supporting ELIQUIS in the prevention of recurrent VTE

The full publication is available to read here

FOOTNOTES

* The AMPLIFY-EXT clinical trial was a 12-month, randomised, double-blind placebo-controlled trial in 2,482 patients with VTE who had been treated for 6–12 months with standard anticoagulation therapy or had completed treatment with ELIQUIS or enoxaparin / warfarin as participants in the AMPLIFY trial and for whom there was clinical uncertainty about the benefit of continuing treatment.1

† The primary efficacy endpoint was the composite of symptomatic recurrent VTE or death from any cause.1 Recurrent VTE included fatal or non-fatal PE and DVT.1

‡ The primary safety endpoint was major bleeding.1 For patients who had more than one event, only the first was counted.1

§ The secondary safety endpoint was the incidence of major or CRNM bleeding events.1 For patients who had more than one event, only the first was counted.1

This link is to a third-party site unaffiliated with the BMS / Pfizer Alliance. Please abide by the terms of use of the site.

ARR = Absolute Risk Reduction   BD = Twice Daily   CI = Confidence Interval   
DVT = Deep Vein Thrombosis   N = Total number of patients in either the ELIQUIS group or the placebo group   n = Number of patients with event   PE = Pulmonary Embolism   RR = Relative Risk   
SmPC = Summary of Product Characteristics   
VTE = Venous Thromboembolism

REFERENCES

  1. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.